title: Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
mesh_terms: D026683:Advisory Committees; D000367:Age Factors; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D018890:Chemoprevention; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
chemical_list: D016588:Anticarcinogenic Agents; D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride